Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) EPS (Weighted Average and Diluted) (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.38 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 7.32% to -$0.38 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.8, a 13.21% decrease, with the full-year FY2024 number at -$1.66, down 12.16% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.38 for Q3 2025 at Orchestra BioMed Holdings, up from -$0.5 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.35 in Q2 2023 to a low of -$1.67 in Q4 2022.
  • A 4-year average of -$0.54 and a median of -$0.43 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 79.04% in 2023, then fell 28.95% in 2025.
  • Orchestra BioMed Holdings' EPS (Weighted Average and Diluted) stood at -$1.67 in 2022, then surged by 79.04% to -$0.35 in 2023, then fell by 22.86% to -$0.43 in 2024, then grew by 11.63% to -$0.38 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's EPS (Weighted Average and Diluted) are -$0.38 (Q3 2025), -$0.5 (Q2 2025), and -$0.49 (Q1 2025).